Urologic Oncology: Seminars and Original Investigations
Original articleDetailed analysis of patient-reported lower urinary tract symptoms and effect on quality of life after robotic radical prostatectomy
Introduction
Robotic-assisted radical prostatectomy (RARP) is a minimally invasive technique, which has become the standard of care in many institutions worldwide for the primary surgical treatment of localized prostate cancer (PCa). Men’s expectations of oncological and functional outcomes after radical prostatectomy are reported to have increased since the introduction of RARP [1], [2]. Additionally, men are actively seeking more accessible patient-centered information about PCa treatments, their associated side effects and the potential impact of treatment on quality of life to better inform their treatment decisions [3].
The evaluation of lower urinary tract function to date after RARP has almost exclusively concentrated on postoperative continence rates with limited information available regarding other potentially bothersome urinary symptoms [4]. Only a minority of reports document individual lower urinary tract symptoms (LUTS) before and after radical prostatectomy even though LUTS are acknowledged to have a significant effect on overall well-being and are often the reason men present for prostate investigation [5], [6], [7], [8].
This highlights the need for a detailed analysis of patient-reported LUTS outcomes after RARP and their effect on overall health-related quality of life (HRQoL) related to baseline status. This study aimed to fill this evidence gap and investigate the impact of RARP on storage, voiding and postmicturition LUTS using the validated International Consultation on Incontinence Modular Questionnaire—Male Lower Urinary Tract Symptoms Long Form (ICIQ-MLUTS) and to correlate these findings with overall and symptom specific HRQoL indices.
Section snippets
Participants
Between July 2012 and September 2015, all men with localized PCa, undergoing RARP at a single center serving a population of 1.2 million people were included. RARP was performed by 3 surgeons at the institution. All patients were invited to complete written validated patient-reported outcome measures (as is standard practice) at baseline (i.e., after diagnosis but before undergoing RARP), at 6, 12, and 18 months after RARP. Patient-reported outcomes were the primary outcome measure in this
Demographic
In total, 357 consecutive men who were planned for RARP were approached and 346 (97%) participated with subsequent follow up. Median age was 65 years (range: 45–74) and postoperative stage was T2 and T3 in 64% and 36% of cases, respectively. The median follow up for the cohort was 19-months (range: 6–49 months). Demographic and questionnaire return rates are summarized in Table 1, Table 2.
Overall quality of life (FACT-P)
Mean overall and domain specific FACT-P scores are illustrated in Fig. 1. The minimally important
Discussion
The present study details the patient-reported outcomes in a contemporary population of men undergoing RARP. Overall, patient-reported quality of life after RARP remains unchanged in the short and medium term. Detailed analysis of LUTS before and after RARP demonstrates that although overall total LUTS and associated bother scores did not change significantly there was a clinically significant change in the composition of urinary symptoms. The change from predominant voiding to predominant
Conclusion
This study highlights that quality of life after RARP results from a complex interplay of factors. Our series suggests that although HRQoL appears unchanged after radical prostatectomy there are significant changes within specific domains. In particular the increase in urinary incontinence which appears to be counterbalanced by small increases in other domains such as emotional well-being. This highlights the need for any future work to include both condition specific and global quality of life
Acknowledgments
The authors would like to thank the urology research nurse team led by Sister Wendy Robson at the Freeman Hospital, Newcastle upon Tyne who were instrumental in making this project successful.
References (23)
- et al.
Systematic review and meta-analysis of studies reporting urinary continence recovery after robotic-assisted radical prostatectomy
Eur Urol
(2012) - et al.
Impact of robot-assisted radical prostatectomy on lower urinary tract symptoms and predictive factors for symptom changes: a longitudinal study
Urology
(2013) - et al.
Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being
J Urol
(2001) - et al.
Long-term outcomes in severe lower urinary tract symptoms in men undergoing robotic-assisted radical prostatectomy
Urology
(2014) - et al.
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument
Urology
(1997) - et al.
Correlation of patient perception of pad use with objective degree of incontinence measured by pad test in men with post-prostatectomy incontinence: The SUFU pad test study
J Urol
(2014) - et al.
Pad count is a poor measure of the severity of urinary incontinence
J Urol
(2013) - et al.
Impact of robot-assisted radical prostatectomy on lower urinary symptoms and predictive factors for symptom changes: a longitudinal study
Urology
(2013) - et al.
The natural history of voiding function after robot assisted laparoscopic prostatectomy
Urol Oncol
(2011) - et al.
Post-sampling mortality and non-response patterns in the English Cancer Patient Experience Survey: Implications for epidemiological studies based on surveys of cancer patients
Cancer Epidemiol
(2016)
Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open radical prostatectomy
J Urol
Cited by (13)
Cognitive-behavioral program to control lower urinary tract symptoms after radical prostatectomy: a randomized clinical trial
2022, Revista Brasileira de EnfermagemDiabetes mellitus lowers the chance of short-term urinary continence recovery in prostate cancer patients undergoing radical prostatectomy
2022, Central European Journal of UrologyDo drugs work for ΟΑΒ following prostate cancer surgery
2020, Current Drug Targets